



Pergamon

Tetrahedron Letters 41 (2000) 4959–4963

TETRAHEDRON  
LETTERS

## Synthesis and asymmetric hydrogenation of 3,5-dioxoheptanedioates. Preparation of enantiomerically pure substituted $\delta$ -valerolactones

Jarosław Kiegiel,<sup>a,\*</sup> Julita Jóźwik,<sup>a</sup> Krzysztof Woźniak<sup>a</sup> and Janusz Jurczak<sup>a,b</sup>

<sup>a</sup>*University of Warsaw, Chemistry Department, Pasteura 1, 02-093 Warsaw, Poland*

<sup>b</sup>*Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland*


Received 29 February 2000; accepted 8 May 2000

### Abstract

The synthesis of 3,5-dioxoheptanedioic acid derivatives based on the reaction of ketene with malonyl chloride was developed. Resulting diketones were subjected to Ru-(*S*)-BINAP-catalyzed asymmetric hydrogenation. The products were transformed into enantiomerically pure 3,5-substituted- $\delta$ -valerolactones. © 2000 Elsevier Science Ltd. All rights reserved.

Substituted tetrahydropyrans are common constituents of many natural products such as mevinic acids,<sup>1</sup> spongistatins,<sup>2</sup> milbemycins,<sup>3</sup> avermectins<sup>4</sup> and phorbaxozoles.<sup>5</sup> We wish to report a novel short approach leading to enantiomerically pure substituted  $\delta$ -valerolactones which are potentially useful in the synthesis of these natural products.<sup>6</sup>

It appeared to us that Ru-BINAP<sup>7</sup> catalyzed asymmetric hydrogenation of 3,5-dioxoheptanedioates could be a route to synthesize enantiomerically pure  $\delta$ -valerolactones and might reveal some interesting features. In order to examine this possibility we were prompted to find an effective procedure for the synthesis of 3,5-dioxoheptanedioates.




**1**

An inspiration came from the work of Stachel<sup>8</sup> who obtained bisdioxinone **1** by the action of ketene on oxalyl chloride in the presence of acetone and the product was used as the substrate for 3,4-dioxohexanedioates.<sup>9</sup> A few attempts to carry out a similar reaction with malonyl chloride

\* Corresponding author.

have been reported<sup>10</sup> showing that only one chlorocarbonyl group reacted. We found that both chlorocarbonyl groups could react with ketene, providing that the intermediate acyl chloride was trapped by the acetone used as a solvent. After work-up and crystallization the resulting bis-dioxinone **2** was obtained in 60% yield (Scheme 1).




Scheme 1. (a) acetone,  $-50^\circ\text{C}$  (60%); (b) ROH,  $130^\circ\text{C}$ , sealed tube, 1 h; (c) *t*-BuOH,  $65^\circ\text{C}$ , 12 h (57%)

Dioxinones are excellent stable sources of ketenes and upon heating they react with alcohols, amines and other nucleophiles.<sup>11</sup> Thus, by heating compound **2** in methanol or *t*-butanol at  $130^\circ\text{C}$  we obtained dimethyl (**3**) and di-*t*-butyl 3,5-dioxoheptanedioate (**4**) in 74 and 94% yields, respectively. We also discovered that if the reaction was carried out under controlled conditions mono-*t*-butyl ester **5** could be obtained in 57% yield. Next, we turned our attention to the asymmetric hydrogenation of ketones **3** and **4**. Diketone **3** gave a mixture of two products: *anti*-diol **6** and *syn*-diol **7** (*meso*) in 88% overall yield and the ratio 5:4, respectively (Scheme 2). The enantiomeric excess of the *anti*-diol **6** could be estimated by  $^1\text{H}$  NMR spectroscopy through the use of the chiral shift reagent  $[\text{Eu}(\text{hfc})_3]$  and amounted to 48%. Similarly, asymmetric hydrogenation of diketone **4** produced an inseparable mixture of diols *anti*-**8** and *syn*-**9** (*meso*) in the ratio 20:9. Though operating with a mixture of diastereoisomers we were also able to estimate the enantiomeric excess of **8** using a chiral shift reagent. The *t*-Bu group singlets clearly split into two equal singlets of *meso*-diol **9** and two singlets reflecting the ratio (82:18, 64% ee) of enantiomers for *anti*-diol **8**.

The results of the asymmetric hydrogenation of diketones **3** and **4** were unsatisfactory due to significant yields of the *meso*-diols and only modest enantiomeric excesses. Mono-*t*-butyl ester **5** containing only one 3-oxoester group promised to give better results. By applying the asymmetric hydrogenation conditions to compound **5**, alcohol **12** was obtained in 97% yield and 87% ee as judged from a  $^1\text{H}$  NMR experiment with the chiral shift reagent (the shift of the *t*-butyl group singlet was observed). Crystallization of compound **12** from 2-propanol enhanced the enantiomeric purity to  $>98\%$  ee. The latter was transformed into ketolactone **13** by heating in *t*-butanol at  $100^\circ\text{C}$ . The same compound was obtained by lactonization of the mixture of diols **8** and **9** and subsequent oxidation of the resulting inseparable mixture of hydroxylactones **10** and **11**. The ketolactone **13** obtained in this manner showed the same sign of specific rotation as the one obtained from **12**, evidence for the same configuration of products **8** and **12**.<sup>12</sup>

However, the problem arose of the absolute configuration of the prevailing enantiomers of compounds **6**, **8** and **12**. Our initial prediction was that asymmetric hydrogenation of **3** and **4** followed the 3,5-diketone rather than the 3-oxoester catalyst coordination pattern and should produce the (*R,R*)-diols as the major products. This prediction was supported by the findings of



Scheme 2. (a) H<sub>2</sub>, 100 atm, 0.5% RuCl<sub>2</sub>[(*S*)-BINAP](*p*-cymene), *t*-BuOH, 50°C, 16 h; (b) *p*-TsOH, CH<sub>2</sub>Cl<sub>2</sub>, reflux, 1 h (92%); (c) Jones' reagent, acetone, 15 min (82%); (d) *t*-BuOH, 100°C, 6 h (88%)

Saburi et al.<sup>13</sup> dealing with asymmetric hydrogenation of methyl 3,5-dioxohexanoate. They obtained the product of 3,5-diketone catalyst chelation in 78% ee. To solve this problem we synthesized the chiral nonracemic diimide **14** in 63% yield by heating bisdioxinone **2** and (1*S*)-bornane-10,2-sultam<sup>14</sup> in toluene at 55°C. Then we attempted to reduce it under various non-chiral conditions in order to obtain a well-defined diastereoisomer for correlation with diol **6**. However, due to the lability of the imide bond, only a few methods proved to be effective for the reduction of **14**. All of these gave mixtures of diastereomers and were not practical. Interestingly, application of (*S*)-Ru–BINAP-catalyzed hydrogenation to compound **14** produced diol **15** in high yield (92%) and high diastereomeric excess (96% de). By crystallization from 2-propanol diastereomerically pure **15** was obtained (Scheme 3). The (3*S*,5*S*) absolute configuration was established by an X-ray diffraction experiment (Fig. 1).





Figure 1. ORTEP representation of **15**



Scheme 3. (a) H<sub>2</sub>, 100 atm, 0.5% RuCl<sub>2</sub>[(*S*)-BINAP](*p*-cymene), CH<sub>2</sub>Cl<sub>2</sub>, 50°C, 16 h (92%, 96% de); (b) NaHCO<sub>3</sub>, MeOH, rt, 24 h (88%); (c) PPTS, benzene, reflux, 15 min (84%)

The stereochemical outcome of the hydrogenation of **14** raised the question as to whether the face selectivity could be reversed by applying the (*R*)-BINAP catalyst. In fact, reversal of face selectivity took place, but the (3*R*,5*R*) equivalent of **15** was obtained in only 78% de. This result suggests that the chiral auxiliary plays an important, but not a crucial, role in the asymmetric induction. Apparently, a matched double asymmetric induction occurs for the (*S*)-BINAP-catalyzed hydrogenation of **14**, while a mismatched situation takes place for the (*R*)-BINAP-catalyzed reaction. The absence of a *syn* hydrogenation product is also an interesting point. We believe that the participation of a nitrogen atom of **14** in chelation of the catalyst is mainly responsible for the stereochemical outcome of the hydrogenation of **14**, but to date it is not quite clear and requires more in depth investigation.

Diol **15** was then transformed into enantiomerically pure dimethyl ester **6** by applying mild methanolysis in the presence of NaHCO<sub>3</sub>. Diols **6** obtained from **3** and **14** showed the same sign of specific rotation.<sup>15</sup> This correlation established the (*S,S*)-configuration for the major enantiomers of diols **6** and **8** and the (*S*)-configuration for compound **12**. In contrast to our earlier predictions this was proof that the major products of the asymmetric hydrogenation of 3,5-dioxoheptanedioates were formed as a result of catalyst chelation to the 3-oxoester rather than to the 3,5-diketone.

Finally, upon refluxing in benzene in the presence of pyridinium *p*-toluenesulfonate compound **6** furnished enantiomerically pure lactone **16**.<sup>16</sup> This compound had been prepared in racemic form by Langlois and Bac<sup>17</sup> for the synthesis of the spiroketal part of milbemycins and avermectins.

In summary, we have developed a short and practical synthesis of 3,5-dioxoheptanedioates and used these compounds in an enantioselective approach to 3,5-disubstituted- $\delta$ -lactones **13** and **16**. Studies aimed to explain all aspects of the asymmetric hydrogenation of 3,5-dioxoheptanedioates are being pursued.

## Acknowledgements

The authors thank the State Committee for Scientific Research of Poland for supporting this work (Grant No. 3 T09A 020 13).

## References

1. (a) Endo, A.; Kuroda, M.; Tsujita, Y. *J. Antibiot.* **1976**, *29*, 1346; (b) Brown, A. G.; Smale, T. C.; King, T. J.; Hasenkamp, R.; Thompson, R. H. *J. Chem. Soc., Perkin Trans. 1* **1976**, 1165.
2. Pettit, G. R.; Cichacz, Z. A.; Gao, F.; Herald, C. L.; Boyd, M. R.; Schmidt, J. M.; Hooper, J. N. A. *J. Org. Chem.* **1993**, *58*, 1302.
3. Mishima, H.; Kurobayashi, C.; Tamura, S.; Sato, S.; Kuwano, H.; Saito, A. *Tetrahedron Lett.* **1975**, 711.
4. Albers-Schönberg, G.; Arison, B. H.; Chabala, J. C.; Douglas, A. W.; Eskola, P.; Fisher, M. H.; Lusi, A.; Mrozik, H.; Smith, J. L.; Tolman, R. L. *J. Am. Chem. Soc.* **1981**, *103*, 4216.
5. (a) Searle, P. A.; Molinski, T. F. *J. Am. Chem. Soc.* **1995**, *117*, 8126; (b) Searle, P. A.; Molinski, T. F.; Brzezinski, L. J.; Leahy, J. W. *J. Am. Chem. Soc.* **1996**, *118*, 9422; (c) Molinski, T. F. *Tetrahedron Lett.* **1996**, *37*, 7879.
6. For recent syntheses and applications of chiral 3-hydroxy-5-substituted- $\delta$ -valerolactones, see: (a) Dunkel, R.; Mentzel, M. *Tetrahedron* **1997**, *53*, 14929; (b) Kaku, H.; Tanaka, M.; Norimine, Y.; Miyashita, Y.; Suemune, H.; Sakai, K. *Tetrahedron: Asymmetry* **1997**, *8*, 195; (c) Wolbers, P.; Hoffmann, H. M. R. *Synthesis* **1999**, *5*, 797; (d) Wolbers, P.; Hoffmann, H. M. R. *Tetrahedron* **1999**, *55*, 1905, and references cited therein.
7. Kitamura, M.; Ohkuma, T.; Inoue, S.; Sayo, N.; Kumobayashi, H.; Akutagawa, S.; Ohta, T.; Takaya, H.; Noyori, R. *J. Am. Chem. Soc.* **1988**, *110*, 629.
8. Stachel, H.-D. *Angew. Chem.* **1957**, *69*, 507.
9. (a) Stachel, H.-D. *Archiv. Pharm. Ber. Dtsch. Pharm. Ges.* **1962**, *295*, 735; (b) Stachel, H.-D.; Jungkenn, M.; Koser-Gnoss, C.; Poschenrieder, H.; Redlin, J. *Liebigs. Ann. Chem.* **1994**, *9*, 961.
10. (a) Beranek, J.; Smrt, J.; Šorm, F. *Collect. Czech. Chem. Commun.* **1954**, *19*, 1231; (b) Smrt, J.; Beranek, J.; Šorm, F. *Collect. Czech. Chem. Commun.* **1955**, *20*, 285; (c) Šorm, F.; Beranek, J.; Smrt, J.; Sicher, J. *Collect. Czech. Chem. Commun.* **1955**, *20*, 593; (d) Polczynski, P.; Paul, H. *J. Prakt. Chem.* **1970**, *312*, 240.
11. Clemens, R. J.; Hyatt, J. A. *J. Org. Chem.* **1985**, *50*, 2431.
12. **13** (> 98% ee from **12**):  $[\alpha]_{\text{D}}^{22}$  -74.8 (*c* 1.0, CHCl<sub>3</sub>). **13** (from the mixture **10+11**):  $[\alpha]_{\text{D}}^{22}$  -27.3 (*c* 1.0, CHCl<sub>3</sub>).
13. Shao, L.; Kawano, H.; Saburi, M.; Uchida, Y. *Tetrahedron* **1993**, *49*, 1997.
14. Oppolzer, W. *Tetrahedron* **1987**, *43*, 1969.
15. Compound **6** (enantiomerically pure from **15**):  $[\alpha]_{\text{D}}^{22}$  21.8 (*c* 1.0, CHCl<sub>3</sub>); (from **3**):  $[\alpha]_{\text{D}}^{22}$  10.3 (*c* 1.0, CHCl<sub>3</sub>).
16. Compound **16**: mp 85–87°C (Et<sub>2</sub>O/hexane);  $[\alpha]_{\text{D}}^{22}$  33.7 (*c* 1.0, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  1.65–1.72 (m, 1H), 2.35–2.41 (m, 1H), 2.48–2.54 (m, 1H), 2.63–2.68 (m, 1H), 2.81–2.87 (m, 1H), 2.89–2.95 (m, 1H), 3.73 (s, 3H), 4.29–4.36 (m, 1H), 4.65–4.71 (m, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  37.2, 39.3, 40.0, 52.1, 63.6, 73.2, 169.8, 170.1.
17. Bac, N. V.; Langlois, Y. *Tetrahedron Lett.* **1988**, *29*, 2819.